SCHEMBL10043750

SCHEMBL10043750

Cc1cc2c(cn1)cc(-c1cc(NC(=O)c3cc(F)c(F)c(F)c3)ccc1C)c(=O)n2C

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SYK P43405 1/20 0.49
MAPK14 Q16539 8/20 0.42
KCNQ3 O43525 3/20 0.42
KCNQ2 O43526 3/20 0.42
POLB P06746 3/20 0.40
MAOB P27338 2/20 0.40
MAPT P10636 2/20 0.40
KCNE1 P15382 2/20 0.40
KCNQ1 P51787 2/20 0.40
ABL1 P00519 2/20 0.40
KDM4E B2RXH2 1/20 0.40
ALDH1A1 P00352 1/20 0.40
HPGD P15428 1/20 0.40
HSD17B10 Q99714 1/20 0.40
KCNQ5 Q9NR82 1/20 0.39
MAPK13 O15264 1/20 0.39
RAF1 P04049 1/20 0.39
PDGFRA P16234 1/20 0.39
MAPKAPK2 P49137 1/20 0.39
MAPK12 P53778 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10043666 0.91 SYK (0.49) SYKMAPK14KCNQ3KCNQ2POLB
SCHEMBL10043924 0.91 MAPK14 (0.46) SYKMAPK14KCNQ3KCNQ2MAOB
SCHEMBL10043664 0.89 SYK (0.49) SYKMAPK14POLBMAPTABL1
SCHEMBL10043705 0.88 MAPT (0.54) SYKMAPK14POLBMAPTABL1
SCHEMBL10043923 0.88 MAOB (0.53) SYKMAPK14KCNQ3KCNQ2POLB
SCHEMBL10043682 0.88 KCNQ3 (0.49) SYKMAPK14KCNQ3KCNQ2POLB
SCHEMBL10072187 0.88 SYK (0.47) SYKMAPK14POLBMAOBMAPT
SCHEMBL10043663 0.87 SYK (0.51) SYKMAPK14KCNQ3KCNQ2POLB
SCHEMBL10043699 0.87 SYK (0.57) SYKMAPK14POLBMAPTKDM4E
SCHEMBL10043675 0.87 SYK (0.49) SYKMAPK14KCNQ3KCNQ2POLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8106068-B2 Compositions and methods for modulating c-kit and PDGFR receptors IRM LLC (BM) 2012-01-31 US disclosed
US-8106068-B2 Compositions and methods for modulating c-kit and PDGFR receptors IRM LLC (BM) 2012-01-31 US disclosed
US-20100081656-A1 COMPOSITIONS AND METHODS FOR MODULATING C-KIT AND PDGFR RECEPTORS IRM LLC (BM) 2010-04-01 US disclosed
US-7678792-B2 Compositions and methods for modulating c-kit and PDGFR receptors IRM LLC (BM) 2010-03-16 US disclosed
US-7678792-B2 Compositions and methods for modulating c-kit and PDGFR receptors IRM LLC (BM) 2010-03-16 US disclosed
US-20080176846-A1 COMPOSITIONS AND METHODS FOR MODULATING C-KIT AND PDGFR RECEPTORS IRM LLC (BM) 2008-07-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080176846-A1 COMPOSITIONS AND METHODS FOR MODULATING C-KIT AND PDGFR RECEPTORS FYN, FLT3, SRC SYK 42/4885MAPK14 117/4885KCNQ3 2453/4885
US-20100081656-A1 COMPOSITIONS AND METHODS FOR MODULATING C-KIT AND PDGFR RECEPTORS FYN, FLT3, SRC SYK 42/4885MAPK14 117/4885KCNQ3 2453/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.